COPDに対する「インダカテロール」 対プラセボ ・QOL(SGRQ)の臨床的意義ある改善:OR=1.63 [95%CI: 1.46-1.84] ・増悪:OR=0.81 [95%CI: 0.70-0.94] ・全死亡:OR=0.42 [95%CI: 0.16-1.08] Cochrane Database Syst Rev . 2015 Jan 10;1(1):CD010139. PMID:25575340 https://t.co/3j9cRuZG99
How does indacaterol compare with placebo & twice-daily beta2-agonists for #COPD? http://t.co/dxHO9wb72E #CochraneEvidence
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for COPD http://t.co/e9tWscMsxL via @CochraneLibrary
(Cochrane) Indacaterol en EPOC http://t.co/A5rMVXs2t8
How does indacaterol compare with placebo & twice-daily beta2-agonists for #COPD? http://t.co/dxHO9wb72E #CochraneEvidence
How does indacaterol compare with placebo & twice-daily beta2-agonists for #COPD? http://t.co/dxHO9wb72E #CochraneEvidence
How does indacaterol compare with placebo & twice-daily beta2-agonists for #COPD? http://t.co/dxHO9wb72E #CochraneEvidence
How does indacaterol compare with placebo & twice-daily beta2-agonists for #COPD? http://t.co/dxHO9wb72E #CochraneEvidence
How does indacaterol compare with placebo & twice-daily beta2-agonists for #COPD? http://t.co/dxHO9wb72E #CochraneEvidence
(Cochrane) Indacaterol en EPOC http://t.co/A5rMVXs2t8
(COCHRANE SUMMARIES) Indacaterol para el tratamiento del EPOC estable http://t.co/v5TNKPDAyc
T1E2A2 #Indacaterol válido para el tto del EPOC estable, similar efecto que β-2 agonistas larga. Vía @FarmaciaOesteAP http://t.co/zz9ZVwPSjq
T1E2A2 #Indacaterol válido para el tto del EPOC estable, similar efecto que β-2 agonistas larga. Vía @FarmaciaOesteAP http://t.co/zz9ZVwPSjq
(COCHRANE SUMMARIES) Indacaterol para el tratamiento del EPOC estable http://t.co/v5TNKPDAyc
EPOC estable→indacaterol vs placebo ↑función pulm y QoL. Beneficio funcional es tan bueno como con ß2 agon [Cochrane] http://t.co/jFa927KmBQ
T1E2A2 #Indacaterol válido para el tto del EPOC estable, similar efecto que β-2 agonistas larga. Vía @FarmaciaOesteAP http://t.co/zz9ZVwPSjq
T1E2A2 #Indacaterol válido para el tto del EPOC estable, similar efecto que β-2 agonistas larga. Vía @FarmaciaOesteAP http://t.co/zz9ZVwPSjq
T1E2A2 #Indacaterol válido para el tto del EPOC estable, similar efecto que β-2 agonistas larga. Vía @FarmaciaOesteAP http://t.co/zz9ZVwPSjq
T1E2A2 #Indacaterol válido para el tto del EPOC estable, similar efecto que β-2 agonistas larga. Vía @FarmaciaOesteAP http://t.co/zz9ZVwPSjq
New #Cochrane Review: Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for COPD http://t.co/XcRjXKpkv5
So, bronchodilation is actually better than placebo (I guess that should come with the definition). http://t.co/Yn5G3M8mU8
RT @tlassers: New review shows once daily bronchodilator has similar effects to twice daily preparation in #COPD http://t.co/TqZ7iVSR2e
Quality of evidence was high to moderate - see SOF tables: http://t.co/umWgM0LBLW
13 trials with 9961 participants included. 10 trial arms vs placebo and 5 trial arms vs twice-daily beta2-agonist http://t.co/hrOCm2oG3J
The clinical benefit of indacaterol for lung function is at least as good as that seen with twice-daily LABA http://t.co/2qfoI0UMvJ
New #Cochrane Review: Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for COPD http://t.co/XcRjXKpkv5
The clinical benefit of indacaterol for lung function is at least as good as that seen with twice-daily LABA http://t.co/2qfoI0UMvJ
(COCHRANE SUMMARIES) Indacaterol para el tratamiento del EPOC estable http://t.co/v5TNKPDAyc
RT @tlassers: New review shows once daily bronchodilator has similar effects to twice daily preparation in #COPD http://t.co/TqZ7iVSR2e
New #Cochrane Review: Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for COPD http://t.co/XcRjXKpkv5
The clinical benefit of indacaterol for lung function is at least as good as that seen with twice-daily LABA http://t.co/2qfoI0UMvJ
The clinical benefit of indacaterol for lung function is at least as good as that seen with twice-daily LABA http://t.co/2qfoI0UMvJ
Quality of evidence was high to moderate - see SOF tables: http://t.co/umWgM0LBLW
13 trials with 9961 participants included. 10 trial arms vs placebo and 5 trial arms vs twice-daily beta2-agonist http://t.co/hrOCm2oG3J
RT @tlassers: New review shows once daily bronchodilator has similar effects to twice daily preparation in #COPD http://t.co/TqZ7iVSR2e
New @CochraneAirways review shows once daily bronchodilator has similar effects to twice daily preparation in #COPD http://t.co/gXYb9kwie7
New @CochraneAirways review shows once daily bronchodilator has similar effects to twice daily preparation in #COPD http://t.co/gXYb9kwie7
(Cochrane) Indacaterol en EPOC estable http://t.co/uDsIdWzWB6
EPOC estable:indacaterol vs placebo ↑func pulm y QoL. Benef funcional tan bueno como ß2 agon [Cochrane] http://t.co/Rl5EbZhexU vía @ernestob
EPOC estable→indacaterol vs placebo ↑función pulm y QoL. Beneficio funcional es tan bueno como con ß2 agon [Cochrane] http://t.co/jFa927KmBQ
EPOC estable→indacaterol vs placebo ↑función pulm y QoL. Beneficio funcional es tan bueno como con ß2 agon [Cochrane] http://t.co/jFa927KmBQ
Indacaterol for the treatment of people with stable COPD http://t.co/Tv07Q2LAZ9